Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges

Cell

Volumn 163, Issue 1, 2015, Pages 39-53

  Day, Chi Ping ^a   Merlino, Glenn ^a   Van Dyke, Terry ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ALKALOID; CISPLATIN; CRIZOTINIB; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEMCITABINE; IMATINIB; LEFLUNOMIDE; OLAPARIB; PACLITAXEL; PEMETREXED; PROCARBAZINE; RAPAMYCIN; RETINOIC ACID; SELUMETINIB; SONIC HEDGEHOG PROTEIN; SUNITINIB; TRASTUZUMAB; VINCRISTINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER PATIENT; CANCER RESEARCH; CANCER THERAPY; CHIMERA; CLINICAL EVALUATION; CLINICAL RESEARCH; COST; DRUG DESIGN; DRUG EFFICACY; GENETICALLY ENGINEERED MOUSE STRAIN; GERMLINE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMATIC CELL; STEM CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; DISEASE MODEL; GENETIC ENGINEERING; NEOPLASMS; XENOGRAFT;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HETEROGRAFTS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS;

EID: 84948464999     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2015.08.068     Document Type: Review

References (108)

1. C. Abate-Shen, K. Politi, L. Chodosh, and K. Olive Mouse Models of Cancer: A Laboratory Manual 2014 CSHL Press
2. J. Ablain, and H. de Thé Retinoic acid signaling in cancer: The parable of acute promyelocytic leukemia Int. J. Cancer 135 2014 2262 2272
3. C.P. Adams, and V.V. Brantner Estimating the cost of new drug development: is it really 802 million dollars? Health Aff. (Millwood) 25 2006 420 428
4. B. Al-Lazikani, U. Banerji, and P. Workman Combinatorial drug therapy for cancer in the post-genomic era Nat. Biotechnol. 30 2012 679 692
5. M. Bailey, Z. Christoforidou, and M.C. Lewis The evolutionary basis for differences between the immune systems of man, mouse, pig and ruminants Vet. Immunol. Immunopathol. 152 2013 13 19
6. J. Barriuso, R. Nagaraju, and A. Hurlstone Zebrafish: a new companion for translational research in oncology Clin. Cancer Res. 21 2015 969 975
7. G.L. Beatty, D.A. Torigian, E.G. Chiorean, B. Saboury, A. Brothers, A. Alavi, A.B. Troxel, W. Sun, U.R. Teitelbaum, R.H. Vonderheide, and P.J. O'Dwyer A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma Clin. Cancer Res. 19 2013 6286 6295
8. C.G. Begley, and L.M. Ellis Drug development: Raise standards for preclinical cancer research Nature 483 2012 531 533
9. C.G. Begley, and J.P.A. Ioannidis Reproducibility in science: improving the standard for basic and preclinical research Circ. Res. 116 2015 116 126
10. E. Burdett, F.K. Kasper, A.G. Mikos, and J.A. Ludwig Engineering tumors: a tissue engineering perspective in cancer biology Tissue Eng. Part B Rev. 16 2010 351 359
11. J. Cao, L. Wan, E. Hacker, X. Dai, S. Lenna, C. Jimenez-Cervantes, Y. Wang, N.R. Leslie, G.X. Xu, H.R. Widlund, and et al. MC1R is a potent regulator of PTEN after UV exposure in melanocytes Mol. Cell 51 2013 409 422
12. O. Casanovas, D.J. Hicklin, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309
13. Z. Chen, K. Cheng, Z. Walton, Y. Wang, H. Ebi, T. Shimamura, Y. Liu, T. Tupper, J. Ouyang, J. Li, and et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response Nature 483 2012 613 617
14. Z. Chen, E. Akbay, O. Mikse, T. Tupper, K. Cheng, Y. Wang, X. Tan, A. Altabef, S.-A. Woo, L. Chen, and et al. Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance Clin. Cancer Res. 20 2014 1204 1211
15. S. Chen, N.E. Sanjana, K. Zheng, O. Shalem, K. Lee, X. Shi, D.A. Scott, J. Song, J.Q. Pan, R. Weissleder, and et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis Cell 160 2015 1246 1260
16. L. Chin, J.N. Andersen, and P.A. Futreal Cancer genomics: from discovery science to personalized medicine Nat. Med. 17 2011 297 303
17. C.W. Chiu, H. Nozawa, and D. Hanahan Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis J. Clin. Oncol. 28 2010 4425 4433
18. G.A. Churchill, D.C. Airey, H. Allayee, J.M. Angel, A.D. Attie, J. Beatty, W.D. Beavis, J.K. Belknap, B. Bennett, W. Berrettini, et al. Complex Trait Consortium The Collaborative Cross, a community resource for the genetic analysis of complex traits Nat. Genet. 36 2004 1133 1137
19. R.B. Corcoran, K.A. Cheng, A.N. Hata, A.C. Faber, H. Ebi, E.M. Coffee, P. Greninger, R.D. Brown, J.T. Godfrey, T.J. Cohoon, and et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models Cancer Cell 23 2013 121 128
20. J. Couzin-Frankel The littlest patient Science 346 2014 24 27
21. M. Das Thakur, F. Salangsang, A.S. Landman, W.R. Sellers, N.K. Pryer, M.P. Levesque, R. Dummer, M. McMahon, and D.D. Stuart Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Nature 494 2013 251 255
22. C.P. Day, J. Carter, C. Bonomi, M. Hollingshead, and G. Merlino Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin Int. J. Cancer 130 2012 190 199
23. C.P. Day, J. Carter, Z. Weaver Ohler, C. Bonomi, R. El Meskini, P. Martin, C. Graff-Cherry, L. Feigenbaum, T. Tüting, T. Van Dyke, and et al. "Glowing head" mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts PLoS ONE 9 2014 e109956
24. V.T. DeVita Jr., and E. Chu A history of cancer chemotherapy Cancer Res. 68 2008 8643 8653
25. L.E. Dow, P.K. Premsrirut, J. Zuber, C. Fellmann, K. McJunkin, C. Miething, Y. Park, R.A. Dickins, G.J. Hannon, and S.W. Lowe A pipeline for the generation of shRNA transgenic mice Nat. Protoc. 7 2012 374 393
26. L.E. Dow, J. Fisher, K.P. O'Rourke, A. Muley, E.R. Kastenhuber, G. Livshits, D.F. Tschaharganeh, N.D. Socci, and S.W. Lowe Inducible in vivo genome editing with CRISPR-Cas9 Nat. Biotechnol. 33 2015 390 394
27. V.M. Faca, K.S. Song, H. Wang, Q. Zhang, A.L. Krasnoselsky, L.F. Newcomb, R.R. Plentz, S. Gurumurthy, M.S. Redston, S.J. Pitteri, and et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development PLoS Med. 5 2008 e123
28. I.J. Fidler, and I.R. Hart Biological diversity in metastatic neoplasms: origins and implications Science 217 1982 998 1003
29. H.H. Fiebig, C. Schuchhardt, H. Henss, L. Fiedler, and G.W. Löhr Comparison of tumor response in nude mice and in the patients Behring Inst. Mitt. 74 1984 343 352
30. K.K. Frese, A. Neesse, N. Cook, T.E. Bapiro, M.P. Lolkema, D.I. Jodrell, and D.A. Tuveson nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer Cancer Discov. 2 2012 260 269
31. G. Gao, L. Chen, and C. Huang Anti-cancer drug discovery: update and comparisons in yeast, Drosophila, and zebrafish Curr. Mol. Pharmacol. 7 2014 44 51
32. L.A. Garraway, and P.A. Jänne Circumventing cancer drug resistance in the era of personalized medicine Cancer Discov. 2 2012 214 226
33. L.A. Garraway Genomics-driven oncology: framework for an emerging paradigm J. Clin. Oncol. 31 2013 1806 1814
34. M.R. Girotti, F. Lopes, N. Preece, D. Niculescu-Duvaz, A. Zambon, L. Davies, S. Whittaker, G. Saturno, A. Viros, M. Pedersen, and et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma Cancer Cell 27 2015 85 96
35. D. Goldstein, R.H. El-Maraghi, P. Hammel, V. Heinemann, V. Kunzmann, J. Sastre, W. Scheithauer, S. Siena, J. Tabernero, L. Teixeira, and et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial J. Natl. Cancer Inst. 107 2015
36. F.J. Gonzalez Cytochrome P450 humanised mice Hum. Genomics 1 2004 300 306
37. E.J. Hagedorn, E.M. Durand, E.M. Fast, and L.I. Zon Getting more for your marrow: boosting hematopoietic stem cell numbers with PGE2 Exp. Cell Res. 329 2014 220 226
38. S. Hanash, and A. Taguchi Application of proteomics to cancer early detection Cancer J. 17 2011 423 428
39. J. Heyer, L.N. Kwong, S.W. Lowe, and L. Chin Non-germline genetically engineered mouse models for translational cancer research Nat. Rev. Cancer 10 2010 470 480
40. M. Hidalgo, F. Amant, A.V. Biankin, E. Budinská, A.T. Byrne, C. Caldas, R.B. Clarke, S. de Jong, J. Jonkers, G.M. Mælandsmo, and et al. Patient-derived xenograft models: an emerging platform for translational cancer research Cancer Discov. 4 2014 998 1013
41. L. Hood, and S.H. Friend Predictive, personalized, preventive, participatory (P4) cancer medicine Nat. Rev. Clin. Oncol. 8 2011 184 187
42. M. Ilie, M. Nunes, L. Blot, V. Hofman, E. Long-Mira, C. Butori, E. Selva, A. Merino-Trigo, N. Vénissac, J. Mouroux, and et al. Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps Cancer Med. 4 2015 201 211
43. P.A. Jänne, A.T. Shaw, J.R. Pereira, G. Jeannin, J. Vansteenkiste, C. Barrios, F.A. Franke, L. Grinsted, V. Zazulina, P. Smith, and et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study Lancet Oncol. 14 2013 38 47
44. J.I. Johnson, S. Decker, D. Zaharevitz, L.V. Rubinstein, J.M. Venditti, S. Schepartz, S. Kalyandrug, M. Christian, S. Arbuck, M. Hollingshead, and E.A. Sausville Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials Br. J. Cancer 84 2001 1424 1431
45. K. Kannan, N.E. Sharpless, J. Xu, R.C. O'Hagan, M. Bosenberg, and L. Chin Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model Proc. Natl. Acad. Sci. USA 100 2003 1221 1225
46. U. Kortmann, J.N. McAlpine, H. Xue, J. Guan, G. Ha, S. Tully, S. Shafait, A. Lau, A.N. Cranston, M.J. O'Connor, and et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts Clin. Cancer Res. 17 2011 783 791
47. L.N. Kwong, J.C. Costello, H. Liu, S. Jiang, T.L. Helms, A.E. Langsdorf, D. Jakubosky, G. Genovese, F.L. Muller, J.H. Jeong, and et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma Nat. Med. 18 2012 1503 1510
48. C. Leaf Why we're losing the war on cancer (and how to win it) Fortune 149 2004 76 82 84-86, 88 passim
49. N. Legrand, A. Ploss, R. Balling, P.D. Becker, C. Borsotti, N. Brezillon, J. Debarry, Y. de Jong, H. Deng, J.P. Di Santo, and et al. Humanized mice for modeling human infectious disease: challenges, progress, and outlook Cell Host Microbe 6 2009 5 9
50. G.J. Lieschke, and P.D. Currie Animal models of human disease: zebrafish swim into view Nat. Rev. Genet. 8 2007 353 367
51. A. Lunardi, and P.P. Pandolfi A co-clinical platform to accelerate cancer treatment optimization Trends Mol. Med. 21 2015 1 5
52. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, and et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
53. D. Maddalo, E. Manchado, C.P. Concepcion, C. Bonetti, J.A. Vidigal, Y.-C. Han, P. Ogrodowski, A. Crippa, N. Rekhtman, E. de Stanchina, and et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system Nature 516 2014 423 427
54. P. Malaney, S.V. Nicosia, and V. Davé One mouse, one patient paradigm: New avatars of personalized cancer therapy Cancer Lett. 344 2014 1 12
55. J. Mattern, M. Bak, E.W. Hahn, and M. Volm Human tumor xenografts as model for drug testing Cancer Metastasis Rev. 7 1988 263 284
56. A. Mendoza, S.-H. Hong, T. Osborne, M.A. Khan, K. Campbell, J. Briggs, A. Eleswarapu, L. Buquo, L. Ren, S.M. Hewitt, and et al. Modeling metastasis biology and therapy in real time in the mouse lung J. Clin. Invest. 120 2010 2979 2988
57. H. Mou, Z. Kennedy, D.G. Anderson, H. Yin, and W. Xue Precision cancer mouse models through genome editing with CRISPR-Cas9 Genome Med. 7 2015 53
58. F.P. Noonan, J.A. Recio, H. Takayama, P. Duray, M.R. Anver, W.L. Rush, E.C. De Fabo, and G. Merlino Neonatal sunburn and melanoma in mice Nature 413 2001 271 272
59. K.P. Olive, and D.A. Tuveson The use of targeted mouse models for preclinical testing of novel cancer therapeutics Clin. Cancer Res. 12 2006 5277 5287
60. K.P. Olive, M.A. Jacobetz, C.J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M.A. Goldgraben, M.E. Caldwell, D. Allard, and et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 2009 1457 1461
61. J.G. Paez, P.A. Jänne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, and et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
62. D.B. Page, M.A. Postow, M.K. Callahan, J.P. Allison, and J.D. Wolchok Immune modulation in cancer with antibodies Annu. Rev. Med. 65 2014 185 202
63. R. Pagliarini, W. Shao, and W.R. Sellers Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure EMBO Rep. 16 2015 280 296
64. P.P. Pandolfi Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia Hum. Mol. Genet. 10 2001 769 775
65. D.R. Pattabiraman, and R.A. Weinberg Tackling the cancer stem cells - what challenges do they pose? Nat. Rev. Drug Discov. 13 2014 497 512
66. K. Pietras, and D. Hanahan A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer J. Clin. Oncol. 23 2005 939 952
67. R.J. Platt, S. Chen, Y. Zhou, M.J. Yim, L. Swiech, H.R. Kempton, J.E. Dahlman, O. Parnas, T.M. Eisenhaure, M. Jovanovic, and et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling Cell 159 2014 440 455
68. P.K. Premsrirut, L.E. Dow, S.Y. Kim, M. Camiolo, C.D. Malone, C. Miething, C. Scuoppo, J. Zuber, R.A. Dickins, S.C. Kogan, and et al. A rapid and scalable system for studying gene function in mice using conditional RNA interference Cell 145 2011 145 158
69. F. Quignon, Z. Chen, and H. de Thé Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukaemia Biochim. Biophys. Acta 1333 1997 M53 M61
70. E. Raymond, L. Dahan, J.-L. Raoul, Y.-J. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, D. Smith, A. Vinik, and et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N. Engl. J. Med. 364 2011 501 513
71. W.C. Reinhold, S. Varma, V.N. Rajapakse, A. Luna, F.G. Sousa, K.W. Kohn, and Y.G. Pommier Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer Hum. Genet. 134 2015 3 11
72. R.R. Riley, S. Duensing, T. Brake, K. Münger, P.F. Lambert, and J.M. Arbeit Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis Cancer Res. 63 2003 4862 4871
73. A.B. Rogers, and J.G. Fox Inflammation and Cancer. I. Rodent models of infectious gastrointestinal and liver cancer Am. J. Physiol. Gastrointest. Liver Physiol. 286 2004 G361 G366
74. J.T. Romer, H. Kimura, S. Magdaleno, K. Sasai, C. Fuller, H. Baines, M. Connelly, C.F. Stewart, S. Gould, L.L. Rubin, and T. Curran Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice Cancer Cell 6 2004 229 240
75. E. Rosfjord, J. Lucas, G. Li, and H.-P. Gerber Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology Biochem. Pharmacol. 91 2014 135 143
76. C.M. Rudin, C.L. Hann, J. Laterra, R.L. Yauch, C.A. Callahan, L. Fu, T. Holcomb, J. Stinson, S.E. Gould, B. Coleman, and et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 N. Engl. J. Med. 361 2009 1173 1178
77. N. Scheer, and C.R. Wolf Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications Xenobiotica 44 2014 96 108
78. N. Scheer, M. Snaith, C.R. Wolf, and J. Seibler Generation and utility of genetically humanized mouse models Drug Discov. Today 18 2013 1200 1211
79. O. Shalem, N.E. Sanjana, E. Hartenian, X. Shi, D.A. Scott, T.S. Mikkelsen, D. Heckl, B.L. Ebert, D.E. Root, J.G. Doench, and F. Zhang Genome-scale CRISPR-Cas9 knockout screening in human cells Science 343 2014 84 87
80. N.E. Sharpless, and R.A. Depinho The mighty mouse: genetically engineered mouse models in cancer drug development Nat. Rev. Drug Discov. 5 2006 741 754
81. L.D. Shultz, N. Goodwin, F. Ishikawa, V. Hosur, B.L. Lyons, and D.L. Greiner Human cancer growth and therapy in immunodeficient mouse models Cold Spring Harb. Protoc. 2014 2014 694 708
82. M. Singh, C.L. Murriel, and L. Johnson Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes Cancer Res. 72 2012 2695 2700
83. L. Soucek, J. Whitfield, C.P. Martins, A.J. Finch, D.J. Murphy, N.M. Sodir, A.N. Karnezis, L.B. Swigart, S. Nasi, and G.I. Evan Modelling Myc inhibition as a cancer therapy Nature 455 2008 679 683
84. A. Sparreboom, O. van Tellingen, W.J. Nooijen, and J.H. Beijnen Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL Cancer Res. 56 1996 2112 2115
85. J. Stebbing, K. Paz, G.K. Schwartz, L.H. Wexler, R. Maki, R.E. Pollock, R. Morris, R. Cohen, A. Shankar, G. Blackman, and et al. Patient-derived xenografts for individualized care in advanced sarcoma Cancer 120 2014 2006 2015
86. M. Steinbauer, M. Guba, G. Cernaianu, G. Köhl, M. Cetto, L.A. Kunz-Schughart, E.K. Geissler, W. Falk, and K.W. Jauch GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice Clin. Exp. Metastasis 20 2003 135 141
87. P. Stiedl, B. Grabner, K. Zboray, E. Bogner, and E. Casanova Modeling cancer using genetically engineered mice Methods Mol. Biol. 1267 2015 3 18
88. K.L. Svenson, D.M. Gatti, W. Valdar, C.E. Welsh, R. Cheng, E.J. Chesler, A.A. Palmer, L. McMillan, and G.A. Churchill High-resolution genetic mapping using the Mouse Diversity outbred population Genetics 190 2012 437 447
89. L. Szabova, S. Bupp, M. Kamal, D.B. Householder, L. Hernandez, J.J. Schlomer, M.L. Baran, M. Yi, R.M. Stephens, C.M. Annunziata, and et al. Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer PLoS ONE 9 2014 e95649
90. J.E. Talmadge, R.K. Singh, I.J. Fidler, and A. Raz Murine models to evaluate novel and conventional therapeutic strategies for cancer Am. J. Pathol. 170 2007 793 804
91. B.A. Teicher Tumor models for efficacy determination Mol. Cancer Ther. 5 2006 2435 2443
92. J.J. Tentler, A.C. Tan, C.D. Weekes, A. Jimeno, S. Leong, T.M. Pitts, J.J. Arcaroli, W.A. Messersmith, and S.G. Eckhardt Patient-derived tumour xenografts as models for oncology drug development Nat. Rev. Clin. Oncol. 9 2012 338 350
93. G. Texidó Genetically engineered animal models for in vivo target identification and validation in oncology Methods Mol. Biol. 986 2013 281 305
94. C.J. Torrance, V. Agrawal, B. Vogelstein, and K.W. Kinzler Use of isogenic human cancer cells for high-throughput screening and drug discovery Nat. Biotechnol. 19 2001 940 945
95. T. Van Dyke, and T. Jacks Cancer modeling in the modern era: progress and challenges Cell 108 2002 135 144
96. L.J. van't Veer, and R. Bernards Enabling personalized cancer medicine through analysis of gene-expression patterns Nature 452 2008 564 570
97. J.C. Walrath, J.J. Hawes, T. Van Dyke, and K.M. Reilly Genetically engineered mouse models in cancer research Adv. Cancer Res. 106 2010 113 164
98. Y. Wang, J.-C. Tseng, Y. Sun, A.H. Beck, and A.L. Kung Noninvasive imaging of tumor burden and molecular pathways in mouse models of cancer Cold Spring Harb. Protoc. 2015 2015 135 144
99. Z. Weaver, S. Difilippantonio, J. Carretero, P.L. Martin, R. El Meskini, A.J. Iacovelli, M. Gumprecht, A. Kulaga, T. Guerin, J. Schlomer, and et al. Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response Cancer Res. 72 2012 5921 5933
100. P.M.K. Westcott, K.D. Halliwill, M.D. To, M. Rashid, A.G. Rust, T.M. Keane, R. Delrosario, K.-Y. Jen, K.E. Gurley, C.J. Kemp, and et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer Nature 517 2015 489 492
101. R.M. White, J. Cech, S. Ratanasirintrawoot, C.Y. Lin, P.B. Rahl, C.J. Burke, E. Langdon, M.L. Tomlinson, J. Mosher, C. Kaufman, and et al. DHODH modulates transcriptional elongation in the neural crest and melanoma Nature 471 2011 518 522
102. K.M. Yamada, and E. Cukierman Modeling tissue morphogenesis and cancer in 3D Cell 130 2007 601 610
103. T.A. Yap, A. Omlin, and J.S. de Bono Development of therapeutic combinations targeting major cancer signaling pathways J. Clin. Oncol. 31 2013 1592 1605
104. N.P. Young, D. Crowley, and T. Jacks Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis Cancer Res. 71 2011 4040 4047
105. X. Zhang, S. Claerhout, A. Prat, L.E. Dobrolecki, I. Petrovic, Q. Lai, M.D. Landis, L. Wiechmann, R. Schiff, M. Giuliano, and et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models Cancer Res. 73 2013 4885 4897
106. B. Zhang, C. Xuan, Y. Ji, W. Zhang, and D. Wang Zebrafish xenotransplantation as a tool for in vivo cancer study Fam. Cancer 14 2015 487 493
107. Y. Zhou, W.M. Rideout 3rd, T. Zi, A. Bressel, S. Reddypalli, R. Rancourt, J.-K. Woo, J.W. Horner, L. Chin, M.I. Chiu, and et al. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas Nat. Biotechnol. 28 2010 71 78
108. L. Zitvogel, L. Apetoh, F. Ghiringhelli, and G. Kroemer Immunological aspects of cancer chemotherapy Nat. Rev. Immunol. 8 2008 59 73